OP-1250-001
68 evidence topics · 8 sources
Objective
Study objectives
“This study (NCT04505826) was an open-label, multicenter, phase 1/2 study designed to identify the maximum tolerated dose (MTD), establish the recommended phase 2 dose (RP2D), and investigate the safety, pharmacokinetics (PK), and antitumor activity of single-agent palazestrant in patients with previously treated ER+/HER2− advanced and metastatic breast cancer” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Primary and secondary objectives
Location and study date
Trial registration and data cutoff of the primary publication
Last participant enrolled
Interim data cutoff: dose escalation and dose expansion
Study design
Dose escalation and dose expansion phases
“Phase 1 of the study comprised a dose-escalation phase (1a) to identify the MTD using a rolling 6 patient dose-escalation design with 7 dose levels. Two doses of palazestrant (60 mg/day and 120 mg/day) were selected for the dose-expansion phase (1b) to further characterize the safety, PK, and preliminary antitumor activity of treatment and to establish the RP2D.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Phase 2 cohorts at the recommended phase 2 dose
“Phase 2 further explored the safety and antitumor activity of palazestrant at the RP2D (120 mg/day) in patients with measurable disease (primary cohort), nonmeasurable evaluable disease (exploratory cohort), and central nervous system (CNS) metastases (exploratory cohort).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The data presented here include patients from phase 1a/1b and the measurable disease and nonmeasurable evaluable disease cohorts from phase 2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dose escalation rules
“Dose escalation cohorts enrolled up to 6 patients at each level; each patient was enrolled in only 1 dose cohort.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the event of 1 of 3 patients experiencing a DLT at a given dose level, a total of 6 patients would be treated at that dose level, and dose escalation would proceed if no more than 1 DLT was observed after 1 cycle of treatment. In the event of 2 or more patients experiencing DLTs at a given dose level, dose escalation stopped, and this dose level was declared the maximally administered dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Selection of two doses for dose expansion
“Dose selection was based on the observation of confirmed PRs at both dose levels” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“and PK data indicating that palazestrant steady-state plasma concentrations reached the predicted efficacy threshold based on estradiol-supplemented preclinical models for both doses” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dose expansion at two dose levels (dose escalation report)
Eligibility criteria
Disease and prior endocrine therapy (all phases)
“Patients eligible for phase 1a of the study included adult men or women of any menopausal status with inoperable histologically or cytologically confirmed ER+/HER2− advanced or metastatic breast cancer who had received at least 1 prior line of endocrine therapy for advanced or metastatic disease for at least 6 months continuously and had received no more than 2 lines of prior chemotherapy regimens for metastatic disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Exclusion of primary endocrine resistance
“Patients who had disease progression within the first 2 years from the start of adjuvant endocrine therapy were not eligible, since these patients were considered to have tumors with primary endocrine resistance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Performance status, disease evaluability, and permitted prior therapies
“Eligible patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and had evaluable disease. Measurable disease per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1) was not a requirement for the dose escalation phase. Prior CDK4/6 inhibitors, fulvestrant, alpelisib, everolimus, or poly-adenosine diphosphate ribose polymerase inhibitors were allowed if discontinued at least 2 weeks prior to the first dose of palazestrant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Additional criteria for phase 1b and phase 2
“In phase 1b/2 of the study, eligible patients met the same key inclusion criteria defined in phase 1a and were also required to have measurable disease per RECIST v1.1, unless they were enrolled in the nonmeasurable disease cohort of patients with nonmeasurable but evaluable disease. In addition, patients must have received no more than 1 prior chemotherapy regimen for metastatic disease and have received at least 1 (but no more than 4) prior lines of endocrine therapy for advanced or metastatic disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Exclusion criteria
“Patients were excluded from all phases of the study if they had impaired cardiac function, cerebral vascular disease, or a recent thromboembolic event, an ongoing serious infection or gastrointestinal disorder that could affect absorption of study treatment, a clinically significant history of liver disease consistent with Child–Pugh class B or C, other comorbidities that could affect the patient’s ability to participate in the study, or any condition requiring medications not permitted during the study (e.g., strong CYP3 A4 inhibitors/inducers).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients who received medications with a known risk of QT interval prolongation or Torsades de Pointes were not permitted to enroll in order to allow comprehensive assessment of QT interval prolongation in the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment
Palazestrant regimen and dose levels
“All patients received oral palazestrant capsules once daily, continuously in 28-day treatment cycles. In this first-in-human study, patients were required to fast for 2 h prior to and 1 h after each palazestrant dose. The initial dose cohort received a dose of palazestrant at 30 mg/day, followed by dose cohorts of 60, 90, 120, 150, 210, and 300 mg/day.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ovarian function suppression and restricted concomitant medications
“Pre- or perimenopausal women were required to use luteinizing hormone–releasing hormone agonists for the duration of the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“proton pump inhibitors and most common antiemetic medications were not permitted” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Selection of 120 mg/day as the recommended phase 2 dose
“Greater clinical benefit at palazestrant 120 mg/day (46%) versus 60 mg/day (19%) led to selection of 120 mg/day as RP2D and study expansion dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Furthermore, because patients stayed on this treatment longer, the CBR was numerically better, and the safety profile was similar to that of the 60 mg dose, this dose was further explored in phase 2 of the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Anticipated dose range after dose escalation
Study outcomes
Rationale for using dose-limiting toxicity as the primary endpoint
Definition of the maximum tolerated dose and dose-limiting toxicities
“The MTD was defined as the highest feasible dose in phase 1a in which fewer than 33% of patients (of at least 6 treated) experienced a treatment-related DLT during cycle 1. In this study, DLTs included any treatment-related fatal adverse event (AE); grade ≥ 3 nonhematologic toxicity (including nausea, vomiting, diarrhea not resolving within 3 days with optimal treatment, and fatigue lasting > 7 days); grade 3 neutropenia (with fever and/or infection); grade 3 thrombocytopenia (with bleeding); grade ≥ 4 hematologic toxicity; grade ≥ 2 AEs that resulted in treatment discontinuation or interruption for at least a week (during cycle 1) or a delay of cycle 2 for at least a week; and protocol-defined elevations of aspartate aminotransferase (AST) or alanine aminotransferase (ALT).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ocular toxicity as a dose-limiting toxicity
Safety and pharmacokinetic assessments
“Safety assessments included the monitoring of AEs, clinical laboratory parameters, electrocardiograms, and vital signs. AE severity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 5.0).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The assessment of palazestrant single- and multiple-dose PK parameters included the maximum plasma concentration (Cmax), minimum plasma concentration (Cmin), average plasma concentration (Cavg), area under the concentration–time curve from 0–24 h (AUC0–24), effective half-life (t1/2), and time to maximum plasma concentration (Tmax).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Efficacy end points: response, clinical benefit rate, and progression-free survival
“Key efficacy end points included assessment of clinical response according to RECIST v1.1; the clinical benefit rate (CBR), defined as the proportion of patients who achieved a complete response (CR), achieved a partial response (PR), or had stable disease (SD) for at least 24 weeks; and progression-free survival (PFS), defined as the time from the date of the first dose to disease progression or death. Biomarker assessments included changes from baseline in circulating tumor DNA (e.g., ESR1 variants) and tumor tissue biomarkers (ERα and Ki67).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Planned sample size and precision
“A sample size of approximately 30 patients per dose group in the phase 1b dose expansion cohorts was expected to provide an estimated precision of ± 19% for any binary event rate assessment. In phase 2, a sample size of approximately 50 patients treated at the RP2D was expected to provide an estimated precision of ± 15% for binary assessments.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Participants enrolled and analyzed
“This study enrolled 146 patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“During the dose escalation phase of the study, 42 patients were treated with once-daily oral palazestrant at doses ranging from 30 to 300 mg” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Baseline demographics and characteristics for all patients treated at 60 mg/day or 120 mg/day (n = 116; including those from the dose-escalation phase) are presented in Table 1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the 116 patients treated in the 60-mg and 120-mg dose cohorts, 92 (79.3%) patients with measurable disease were evaluable for tumor response.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Description of analysis sets
Analysis populations in the primary publication
“All DLT analyses (phase 1a) were performed in patients enrolled in the study during cycle 1 and who either received 75% of the planned palazestrant doses or experienced a DLT during cycle 1. All PK analyses were performed in patients who received at least 1 dose of palazestrant and had adequate postbaseline PK samples for characterization of PK parameters. All safety analyses were performed and PFS assessed in patients who received at least 1 dose of palazestrant. Clinical response (CR or PR) was assessed in patients who received at least 1 cycle of palazestrant, had measurable disease at baseline, and had at least 1 postbaseline tumor assessment. CBR was assessed in patients who received at least 1 cycle of palazestrant, had at least 1 postbaseline tumor assessment, and started their first dose at least 24 weeks before data cutoff. Patients who discontinued study treatment without radiographic progression within 24 weeks from the first dose were not included in the CBR analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Analysis sets in the statistical analysis plan
Results
Participant disposition
Treatment status and reasons for discontinuation at 60 or 120 mg/day
“Among all patients treated with 60 or 120 mg/day palazestrant, 102/116 (87.9%) had discontinued treatment at the time of data cutoff (July 7, 2023) and 14 (12.1%) were ongoing. Reasons for treatment discontinuation included radiographic disease progression (n = 78 [67.2%]), clinical disease progression (i.e., without disease progression per RECIST v1.1) (n = 11 [9.5%]), AEs (n = 7 [6.0%]), withdrawal of consent (n = 4 [3.4%]), and other reasons (n = 2 [1.7%]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics
Baseline characteristics at 60 and 120 mg/day
Prior treatment at 60 and 120 mg/day
“Patients had a median age of 61 years, the majority had measurable or visceral disease (84.5% and 73.3%, respectively), 74.1% of patients received at least 2 prior lines of systemic therapy in the advanced setting (median 2; range, 1–8), approximately two-thirds (63.8%) received at least 2 prior lines of endocrine therapy in the advanced setting (median 2; range, 1–5), and all but 5 patients (95.7%) received prior CDK4/6 inhibitor therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Efficacy results
Response and clinical benefit by dose level
Confirmed response after the data cutoff and tumor shrinkage at 120 mg/day
“One additional patient treated at the RP2D had a cPR after the data cutoff date for a total of 4 confirmed PRs (6.0%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A reduction in tumor size (percentage change less than zero) was experienced by 25/64 (39.1%) patients treated at the R2PD, including 8/64 (12.5%) who experienced a > 30% reduction” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Duration of treatment at 120 mg/day
“Palazestrant treatment led to prolonged disease stabilization, with 32/86 (37.2%) of patients treated at 120 mg/day remaining on treatment for ≥ 6 months and 6 (7.0%) remaining on treatment for ≥ 1 year” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Progression-free survival at 120 mg/day, overall and with ESR1 mutation
“The median PFS for patients receiving 120 mg/day palazestrant was 4.8 months (95% CI, 3.5–7.1), with a 6-month PFS rate of 39%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patients with cancers with ESR1 mutations treated at the R2PD, the median PFS was 5.6 months (95% CI, 4.8-NE), and the 6-month PFS rate was 47%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Clinical benefit rate at 120 mg by subgroup (conference presentation)
“All patients: 40% (32/81)” (opens the source at this quote in a new tab)
“Prior fulvestrant: 41% (22/54)” (opens the source at this quote in a new tab)
“ESR1 mutation: 52% (17/33)” (opens the source at this quote in a new tab)
“ESR1 wild-type: 32% (12/38)” (opens the source at this quote in a new tab)
“3 cPRs and 2 uPRs† in 66 response-evaluable patients” (opens the source at this quote in a new tab)
Second- or third-line subset at 120 mg (conference presentation)
| Population | Median PFS, months [95% CI] | 6-month PFS | CBR |
|---|---|---|---|
| All participants (n=86) | “4.6 [3.5, 6.5]” | “38%” | “40%” |
| Second or third line with or without chemotherapy (n=49) | “7.2 [3.7, 7.8]” | “54%” | “48%” |
| ESR1 mutation (n=36) | “5.6 [3.7, 7.8]” | “46%” | “52%” |
| ESR1 mutation, second or third line with or without chemotherapy (n=23) | “7.3 [5.0, NA]” | “62%” | “59%” |
Second- or third-line subset at 120 mg by ESR1 status (company announcement)
ESR1 wild-type participants at 120 mg (company announcement)
Second- or third-line subset in the primary publication
“In an analysis of 49 patients who received palazestrant as second- or third-line therapy with or without prior chemotherapy, the median PFS was extended to 7.2 months, with a CBR of 48% overall. Similarly, patients with cancers with ESR1 mutations had an extended PFS of 7.3 months and CBR of 59% in this subanalysis” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Clinical benefit by on-treatment change in ESR1 mutations
“In patients who had been treated with the RP2D of 120 mg/day palazestrant and had ctDNA available for analysis, the CBR was 73% (8/11) in patients who had a reduction in ESR1 mutations and 25% (8/32) in those who did not have a reduction in ESR1 mutations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dose escalation efficacy
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Dose escalation: dose-limiting toxicities
“Palazestrant doses of up to 300 mg/day resulted in no DLTs, and the MTD was not reached. The majority of treatment-emergent adverse events (TEAEs) were grade 1 or 2 in severity in all dose-escalation cohorts of palazestrant” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adverse events occurring in at least 15% of participants, n (%)
Treatment-emergent adverse events at 120 mg/day
“Most patients (95.3%) who received the RP2D of 120 mg/day experienced ≥ 1 TEAE of any grade, most commonly nausea (62.8%), vomiting (29.1%), and fatigue (25.6%). The majority of TEAEs were grade 1 or 2 in severity. Grade 3 TEAEs were reported in 21 (24.4%) patients, most commonly vomiting (n = 4 [4.7%]), neutropenia, nausea, and fatigue (n = 3 each [3.5%]). Eight (9.3%) patients treated with 120 mg/day palazestrant also experienced grade 4 TEAEs, including neutropenia (n = 6), acute respiratory failure (n = 1), and 1 patient experienced 3 grade 4 events (pulmonary embolism, diverticulitis, and acute left ventricular failure).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment-related adverse events at 120 mg/day
“The most common TRAEs of any grade were nausea (54.7%), vomiting (24.4%), fatigue (19.8%), neutropenia (20.9%), and headache (15.1%). Grade 3 treatment-related events occurred in 10 (11.6%) patients. Nausea and neutropenia (n = 3 each [3.5%]) and vomiting and fatigue (n = 2 each [2.3%]) were the most common grade 3 TRAEs. Treatment-related grade 4 neutropenia occurred in 5 (5.8%) patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patients treated with the RP2D of palazestrant, the rate of treatment-related diarrhea of any grade was 13%, and there were no grade ≥ 3 events.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Discontinuations due to adverse events and management of grade 4 neutropenia
“Seven patients discontinued palazestrant due to AEs, of which 5 were assessed as related to palazestrant: grade 4 febrile neutropenia with no evidence of infection, grade 4 neutropenia, grade 3 nausea, grade 3 international normalized ratio increase, and grade 2 fatigue. Of the 6 patients with grade 4 neutropenia, 3 events resolved with a dose interruption (1 week) followed by a dose reduction (to 60 mg/day in 1 patient and to 90 mg/day in 2 patients); these patients continued treatment with no further neutropenia. In 3 patients, grade 4 neutropenia resolved following discontinuation of palazestrant. Grade 4 neutropenia occurred in 1 patient, concurrent with disease progression, and was assessed as not related to palazestrant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Timing of grade 4 neutropenia and monitoring in ongoing studies
“While grade 4 neutropenia events occurred approximately 6-8 weeks after initiation of palazestrant, these were managed with dose interruptions or discontinuations and/or with colony-stimulating factors” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mechanism underlying neutropenia is unknown, and no corresponding trends were observed in preclinical studies of palazestrant (unpublished data).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All ongoing studies with palazestrant include proactive monitoring of blood counts that is more frequent during first 6–8 weeks after initiation of palazestrant, with the possibility for dose reduction or interruption following the detection of grade 3 or 4 neutropenia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prior CDK4/6 inhibitor exposure among participants with grade 4 neutropenia
QTcF, bradycardia, and photopsia at 120 mg/day
“There were no clinically significant changes in the QT interval corrected by the Fridericia formula (QTcF) in any patients treated with palazestrant, and no QTcF values exceeded 500 ms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“TEAEs of oral SERDs observed in less than 10% of patients treated at the RP2D of palazestrant included bradycardia (9%) and photopsia (5%); all bradycardia and photopsia events were grade 1, and there were no dose modifications, interruptions, or discontinuations due to these events.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dose escalation: photopsia, bradycardia, and dose reductions
Grade 3 treatment-related events at 60 and 120 mg in the interim analysis
Study limitations
Summary
OP-1250-001 was an open-label phase 1/2 study without a comparator arm, which the authors state limits interpretation of the safety profile and antitumor activity. Efficacy estimates come from dose cohorts of 30 participants at 60 mg/day and 86 at 120 mg/day, and only 6 participants were enrolled at 90 mg/day, during dose escalation. Response and CBR analyses used restricted populations: response required measurable disease and a postbaseline assessment (66 response-evaluable participants at 120 mg/day), and the CBR analysis excluded participants who discontinued without radiographic progression within 24 weeks. Two reports of the 120 mg cohort give different values: the peer-reviewed publication reports a CBR of 45.7% in 70 evaluable participants and a median PFS of 4.8 months, and the 2023 conference presentation reports a CBR of 40% (32/81) and a median PFS of 4.6 months. The study excluded primary endocrine resistance; fasted dosing, the exclusion of proton pump inhibitors and most common antiemetics, and a relatively large capsule may have increased gastrointestinal events. The central nervous system metastases cohort is not included in the publication, and the association between ESR1 mutation reduction and CBR is based on 11 and 32 participants (CBR 73% [8/11] versus 25% [8/32]). All 116 participants treated at 60 or 120 mg/day were women, 33.6% had received prior chemotherapy, and 8.6% had received 5 or more prior lines of therapy in the advanced setting.
Open-label design without a comparator arm
“Limitations of this study, as with most early-phase clinical trials, include its open-label design and lack of a comparator arm that limit the interpretation of the observed safety profile and antitumor activity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Population excluded primary endocrine resistance
Study conditions that may have increased gastrointestinal events
“In this study, palazestrant was administered in the fasted state, proton pump inhibitors and most common antiemetic medications were not permitted, and the drug was administered in a relatively large capsule formulation, each of which could have contributed to an increased incidence of gastrointestinal events.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cross-trial comparisons and small biomarker subgroups
“While between-study comparisons should always be made with caution because of variations in patient populations, equivalent dosing levels, and study designs” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“While the correlation between reductions in ESR1 mutations and CBR is encouraging based on a small number of patients, these findings should be further explored in larger trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote